Table 2.

Showing clinical trials of Mapatumumb either alone or in combinational approaches

Drug used	Phase	Pts No. (=)	Study population	Safety	Best response	Reference or Trial number
Combination of Mapatumumab with
Paclitaxel and carboplatin	I	27	Advanced solid tumours	Safe with paclitaxel and cisplatin up to 20 mg·kg−1 with no occurrence of dose limiting toxicity	Partial response (5), stable disease (12)	109
	Ib	28	Advanced solid tumours	Pharmacokinetic profile of HGS-ETR1 not affected by paclitaxel and carboplatin	Partial response (6), stable disease103	109
Paclitaxel and carboplatin	II R	111	First-line advanced non-small cell lung carcinoma	The results do not support further evaluation in combination with paclitaxel, carboplatin in patients with advanced non-small cell lung carcinoma	Similar to paclitaxel, carboplatin alone	110 NCT00583830
Gemcitabine and cisplatin	Ib	49	Advanced solid tumours	Safe with gemcitabine and cisplatin at doses up to 30 mg·kg−1	Partial response (12), stable disease111	112
Cisplatin and radiotherapy	Ib/II	42*	Objective is 42 Patient with first-line advanced cervical cancer	Recruiting	Not reported	NCT01088347
Sorafenib	Ib	19	Advanced hepatocellular carcinoma and chronic viral hepatitis	Safe with sorafenib at doses up to 30 mg·kg−1	Partial response (2), stable disease (4)	NCT00712855
	II	100*	101 patients were randomized; 51 in the placebo–sorafenib arm and 50 patients in the mapatumumab–sorafenib arm	Overall, the frequency of AEs, serious AEs (SAEs), and severe AEs was comparable between the two treatment arms. Only increased lipase was considered related to mapatumumab by investigators.	NO clinical or statistical significance were noted between the 2 arms in terms of median PFS or median OS	NCT01258608
Bortezomib	II R	104	Relapsed/Refractory multiple myeloma	No adverse effects but no benefit	Similar to bortezomib alone	NCT00315757
Mapatumumab or TRM1 or HGS-ETR1 alone
	Ia	49	Advanced solid tumours	Safe and well tolerated up to 20 mg·kg−1 i.v. – half-life 18–21 days	Stable disease (19)	113
	Ia	41	Advanced solid tumours	Peak plasmatic concentrations compatible with preclinical studies	Stable disease (12)	114
	Ib/ II	40	Relapsed/Refractory non-Hodgkin lymphoma	Three clinical responses out of 15 follicular lymphoma patients.	Complete response (2), partial response (1), stable disease (12)	115 NCT00094848
	II	32	Relapsed/Refractory stage IIIb/IV or recurrent non-small cell lung carcinoma	No adverse effects, but no clinical activity demonstrated	Stable disease (9)	116 NCT00092924
	II	38	Refractory colorectal cancer	-	Stable disease (12)	117

*Estimation/expected. Clinical trials number listed in this table can be found at: http://www.clinicaltrials.gov